A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of MT-8554 in Female Subjects Experiencing Vasomotor Symptoms
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2017
At a glance
- Drugs MT 8554 (Primary)
- Indications Vasomotor symptoms
- Focus Adverse reactions
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 09 Feb 2017 Status changed from recruiting to completed.
- 27 Jun 2016 Status changed from not yet recruiting to recruiting.
- 21 Jun 2016 New trial record